We’re happy to share that Johan van Wyk, Resident Director of Cyclarity Therapeutics Australia Pty Ltd, represented Cyclarity on the clinical panel at AusBiotech 2025 Conference. He discussed the clinical progress of Cyclarity’s UDP-003 and explained why Australia was chosen as the strategic location for conducting Phase 1 trials.
About Cyclarity Therapeutics, Inc.
Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.cyclaritytx.com or send an email to press@cyclaritytx.com
Contact:
Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com